• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用甲状腺素补充剂成功治疗血管内皮生长因子升高的难治性TAFRO综合征。

Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.

作者信息

Oka Satoko, Ono Kazuo, Nohgawa Masaharu

机构信息

Division of Hematology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.

Division of Pathology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.

出版信息

Clin Case Rep. 2018 Feb 21;6(4):644-650. doi: 10.1002/ccr3.1430. eCollection 2018 Apr.

DOI:10.1002/ccr3.1430
PMID:29636932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5889265/
Abstract

Although the clinical significance of hypothyroidism in TAFRO syndrome is unknown, vascular endothelial growth factor (VEGF) levels decreased with improvements in the condition of our refractory TAFRO cases after thyroxine supplement therapy. Our results indicate that elevated VEGF levels are a potential factor in the pathogenesis and anasarca of TAFRO syndrome with hypothyroidism.

摘要

虽然甲状腺功能减退症在TAFRO综合征中的临床意义尚不清楚，但在我们难治性TAFRO病例中，补充甲状腺素治疗后，血管内皮生长因子（VEGF）水平随着病情改善而下降。我们的结果表明，VEGF水平升高是伴有甲状腺功能减退症的TAFRO综合征发病机制和全身性水肿的一个潜在因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/535c064f151a/CCR3-6-644-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/bd467025ab57/CCR3-6-644-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/9de8f204f92b/CCR3-6-644-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/f05efaba99b5/CCR3-6-644-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/535c064f151a/CCR3-6-644-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/bd467025ab57/CCR3-6-644-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/9de8f204f92b/CCR3-6-644-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/f05efaba99b5/CCR3-6-644-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd73/5889265/535c064f151a/CCR3-6-644-g004.jpg

相似文献

1
Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.使用甲状腺素补充剂成功治疗血管内皮生长因子升高的难治性TAFRO综合征。
Clin Case Rep. 2018 Feb 21;6(4):644-650. doi: 10.1002/ccr3.1430. eCollection 2018 Apr.
2
Subclinical Hypothyroidism in TAFRO Syndrome.TAFRO综合征中的亚临床甲状腺功能减退症
Intern Med. 2019 Sep 15;58(18):2615-2620. doi: 10.2169/internalmedicine.2717-19. Epub 2019 Jun 7.
3
Severe refractory TAFRO syndrome requiring continuous renal replacement therapy complicated with infection in the lungs and myocardial infarction: an autopsy case report and literature review.需要持续肾脏替代治疗的严重难治性TAFRO综合征并发肺部感染和心肌梗死：一例尸检病例报告及文献复习
Ren Replace Ther. 2018;4(1):16. doi: 10.1186/s41100-018-0157-8. Epub 2018 Apr 4.
4
Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.血管内皮生长因子（VEGF）表达增加与iMCD-TAFRO的发病机制
Biomedicines. 2024 Jun 14;12(6):1328. doi: 10.3390/biomedicines12061328.
5
TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.TAFRO 综合征致肾小球微血管病：病例报告并文献复习。
BMC Nephrol. 2019 Oct 17;20(1):375. doi: 10.1186/s12882-019-1574-9.
6
Tufted-angioma-like lesion associated with vascular endothelial growth factor and interleukin-6 in TAFRO syndrome: Is it a common histological feature of multicentric Castleman disease/POEMS syndrome?TAFRO综合征中与血管内皮生长因子和白细胞介素-6相关的簇状血管瘤样病变：它是多中心Castleman病/POEMS综合征的常见组织学特征吗？
J Cutan Pathol. 2019 Apr;46(4):280-284. doi: 10.1111/cup.13415. Epub 2019 Feb 6.
7
Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.TAFRO 综合征的肾脏病理表现：血栓性微血管病与膜增生性肾小球肾炎之间是否存在连续性？病例报告及文献复习。
Front Immunol. 2019 Jun 28;10:1489. doi: 10.3389/fimmu.2019.01489. eCollection 2019.
8
Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).患者出现肝弯曲杆菌空肠亚种感染（特发性多中心 Castleman 病伴血小板减少、全身性水肿、发热、网状纤维纤维化和器官肿大（TAFRO）综合征）。
Pathol Int. 2019 Oct;69(10):572-579. doi: 10.1111/pin.12856.
9
Borderline Case of TAFRO Syndrome and POEMS Syndrome.TAFRO 综合征和 POEMS 综合征的交界病例。
Intern Med. 2021 May 15;60(10):1589-1595. doi: 10.2169/internalmedicine.5860-20. Epub 2020 Dec 15.
10
Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab.托珠单抗耐药 TAFRO 综合征一例血清 VEGF 水平的序贯变化，利妥昔单抗治疗有效。
Mod Rheumatol Case Rep. 2021 Jan;5(1):145-151. doi: 10.1080/24725625.2020.1789304. Epub 2020 Jul 15.

引用本文的文献

1
Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.血管内皮生长因子（VEGF）表达增加与iMCD-TAFRO的发病机制
Biomedicines. 2024 Jun 14;12(6):1328. doi: 10.3390/biomedicines12061328.
2
Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.血小板减少症、发热、全身水肿和甲状腺功能减退的不明原因：伴有血栓性微血管病肾组织学的 TAFRO 综合征。
BMJ Case Rep. 2020 Jun 30;13(6):e234155. doi: 10.1136/bcr-2019-234155.
3
TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient.

本文引用的文献

1
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.HIV和HHV-8阴性的Castleman病的临床和病理特征
Blood. 2017 Mar 23;129(12):1658-1668. doi: 10.1182/blood-2016-11-748855. Epub 2017 Jan 18.
2
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.HHV-8阴性/特发性多中心Castleman病的国际循证共识诊断标准。
Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.
3
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.
TAFRO综合征：一名白种人患者出现严重内分泌病的病例。
Cureus. 2019 Jun 19;11(6):e4946. doi: 10.7759/cureus.4946.
4
Subclinical Hypothyroidism in TAFRO Syndrome.TAFRO综合征中的亚临床甲状腺功能减退症
Intern Med. 2019 Sep 15;58(18):2615-2620. doi: 10.2169/internalmedicine.2717-19. Epub 2019 Jun 7.
TAFRO综合征的拟诊标准、疾病严重程度分类及治疗策略，2015年版
Int J Hematol. 2016 Jun;103(6):686-92. doi: 10.1007/s12185-016-1979-1. Epub 2016 Mar 18.
4
Idiopathic multicentric Castleman's disease: a systematic literature review.特发性多中心Castleman病：一项系统的文献综述
Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17.
5
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.TAFRO 综合征的临床病理分析显示了一种独特的 HH V-8 阴性多中心 Castleman 病亚型。
Am J Hematol. 2016 Feb;91(2):220-6. doi: 10.1002/ajh.24242.
6
[Autoimmune hemolytic anemia in a patient with TAFRO syndrome].[TAFRO综合征患者的自身免疫性溶血性贫血]
Rinsho Ketsueki. 2015 Nov;56(11):2346-50. doi: 10.11406/rinketsu.56.2346.
7
[Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease].利妥昔单抗治疗TAFRO综合征（多中心Castleman病的一种变异型）的疗效
Rinsho Ketsueki. 2014 Mar;55(3):350-5.
8
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.HHV-8 阴性、特发性多中心 Castleman 病：生物学、发病机制和治疗的新见解。
Blood. 2014 May 8;123(19):2924-33. doi: 10.1182/blood-2013-12-545087. Epub 2014 Mar 12.
9
First IL-6-blocking drug nears approval for rare blood disorder.首款阻断白细胞介素-6的药物有望获批用于治疗罕见血液疾病。
Nat Med. 2013 Oct;19(10):1193. doi: 10.1038/nm1013-1193.
10
Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).卡斯尔曼-小岛病（TAFRO综合征）：一种新型全身性炎症性疾病，其特征为一系列症状，即血小板减少、腹水（全身性水肿）、小细胞性贫血、骨髓纤维化、肾功能不全和器官肿大：福岛会议（2012年6月6日）和名古屋会议（2012年9月22日）的现状报告及总结
J Clin Exp Hematop. 2013;53(1):57-61. doi: 10.3960/jslrt.53.57.